



Pharmaceuticals Limited

Registered & Corporate Office :

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,
Opp. SBI Executive Enclave, Banjara Hills,
Hyderabad - 500 034, Telangana, INDIA.
Tel : +91-40-2525 9999, Fax : +91-40-2525 9889
CIN : L24239TG1987PLC008066
Email: info@smspharma.com, www.smspharma.com

Date: 02nd May, 2025

To
The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

Security Code: 532815

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E), Mumbai
- 400 051.

Symbol: SMSPHARMA

Dear Sir/Madam,

Sub: Receives Prequalification approval from World Health Organization Geneva for the Company's manufacturing facility located at Visakhapatnam, Andhra Pradesh.

Ref: Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.

We wish to inform you that, the Company's Visakhapatnam, manufacturing facility (Vizag Plant) receives Prequalification approval from World Health (WHO) Geneva. Please find the enclosed Company statement titled "**Vizag plant receives WHO Geneva prequalification approval**"

The above information will also be made available on the website of the Company at www.smspharma.com

This is for your information and records.

Thanking you

Yours Faithfully
For SMS Pharmaceuticals Limited

Thirumalesh Tumma
Company Secretary



May 2, 2025

Vizag plant receives WHO Geneva prequalification

SMS Pharmaceuticals Limited (SMS Pharma) (NSE: SMSPHARMA; BSE: 532815) is pleased to share that our Unit VII manufacturing facility in Visakhapatnam, Andhra Pradesh, has received prequalification approval from the World Health Organisation (WHO) Geneva. This significant milestone enhances our global regulatory standing and enables the company to increase its presence in the global market for Anti-Retroviral (ARV) APIs.

Commenting on this achievement, Mr. P. Vamsi Krishna, Executive Director, stated:

"The WHO Geneva prequalification reflects the company's strong compliance with stringent international regulatory standards, reinforcing its reputation for quality, reliability, and global competitiveness."

About SMS Pharmaceuticals Limited

Established in 1990, SMS Pharmaceuticals Limited is a diversified and integrated pharmaceutical company specialising in API and intermediates for global customers. The Company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag, with capacities of 120 KL and 3,000 KL, respectively. Supported by strong in-house R&D capabilities, the Company has a proven track record of delivering quality products across a diversified portfolio of therapeutic segments, serving as a trusted partner to a global customer base in over 70 countries.

For any further information, please contact:

Company	Investor relations
SMS Pharmaceuticals Limited	Eqspont Partners LLP
Mr. Thirumalesh Tumma Email: complianceofficer@smspharma.com	Mr. Aditya Dutta Email: smspharma.IR@eqspont.com

DISCLAIMER

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. SMS Pharmaceuticals Limited will not be in any way responsible for any action taken based on such statements and discussions; undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.